- Home
- ZCMD vs TPST Comparison
ZCMD vs TPST Comparison
Compare ZCMD & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- TPST
- Stock Information
- Founded
- ZCMD 2012
- TPST 2011
- Country
- ZCMD China
- TPST United States
- Employees
- ZCMD 111
- TPST N/A
- Industry
- ZCMD Other Consumer Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- TPST Health Care
- Exchange
- ZCMD Nasdaq
- TPST Nasdaq
- Market Cap
- ZCMD 28.5M
- TPST 33.0M
- IPO Year
- ZCMD 2020
- TPST N/A
- Fundamental
- Price
- ZCMD $1.14
- TPST $6.92
- Analyst Decision
- ZCMD
- TPST Hold
- Analyst Count
- ZCMD 0
- TPST 3
- Target Price
- ZCMD N/A
- TPST $30.00
- AVG Volume (30 Days)
- ZCMD 506.1K
- TPST 86.6K
- Earning Date
- ZCMD 01-01-0001
- TPST 08-07-2025
- Dividend Yield
- ZCMD N/A
- TPST N/A
- EPS Growth
- ZCMD N/A
- TPST N/A
- EPS
- ZCMD N/A
- TPST N/A
- Revenue
- ZCMD $15,864,773.00
- TPST N/A
- Revenue This Year
- ZCMD N/A
- TPST N/A
- Revenue Next Year
- ZCMD N/A
- TPST N/A
- P/E Ratio
- ZCMD N/A
- TPST N/A
- Revenue Growth
- ZCMD N/A
- TPST N/A
- 52 Week Low
- ZCMD $0.95
- TPST $5.35
- 52 Week High
- ZCMD $2.97
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- ZCMD 48.00
- TPST 46.64
- Support Level
- ZCMD $1.13
- TPST $7.06
- Resistance Level
- ZCMD $1.24
- TPST $7.64
- Average True Range (ATR)
- ZCMD 0.11
- TPST 0.26
- MACD
- ZCMD -0.01
- TPST 0.00
- Stochastic Oscillator
- ZCMD 21.84
- TPST 22.10
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.